Marizomib exerts antitumour effects in GBM by inducing caspase 9-dependent apoptosis [173], and it could potentially achieve synergistic effect with TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist [174]. Here, TNFSF10 is linked to glioblastoma.